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ABSTRACT
Pharmacoepidemiology studies are increasingly used for research
into safe prescribing in chronic kidney disease (CKD). Typically,
patients prescribed a drug are compared with patients who are not
on the drug and outcomes are compared to draw conclusions
about the drug effects. This review article aims to provide the read-
erwith a framework to critically appraise such research. A key con-
cern in pharmacoepidemiology studies is confounding, in that
patients who have worse health status are prescribed more drugs
or different agents and their worse outcomes are attributed to the
drugs not the health status. It may be challenging to adjust for this
using statisticalmethods unless a comparison groupwith a similar
health status but who are prescribed a different (comparison)
drug(s) is identiﬁed. Another challenge in pharmacoepidemiology
is outcome misclassiﬁcation, as people who are more ill engage
more often with the health service, leading to earlier diagnosis
in people who are frequent attenders. Finally, using replication co-
horts with the same methodology in the same type of health sys-
tem does not ensure that ﬁndings are more robust. We use two
recent papers that investigated the association of proton pump in-
hibitor drugs with CKD as a device to review the main pitfalls of
pharmacoepidemiology studies and how to attempt to mitigate
against potential biases that can occur.
Keywords: bias, chronic kidney disease, observational studies,
pharmacoepidemiology, proton pump inhibitors
INTRODUCTION
Two recent papers reporting an association between proton
pump inhibitors (PPIs) and incident chronic kidney disease
(CKD) [1, 2] have led to much discussion among nephrologists.
Although the limitations of these studies have been mentioned
by the authors of the papers and discussed in editorials [3–5],
anecdotally these studies are leading to a change in clinical
practice (Figure 1). These studies are well-conducted, thought-
ful analyses withmany strengths. The aim of this article is not to
criticize them, but to highlight the caveats that need to be con-
sidered when drawing causal conclusions from associations re-
ported in pharmacoepidemiological studies. We have not
considered every nuance of the papers, but focused on areas
that are important for the broader principles.
The results of an epidemiological study linking a medication
with a health outcome can be explained in four ways. First, there
may indeed be a causal association between PPIs and the devel-
opment of CKD. The second possibility is that the results may
have arisen by chance. However, the large sample sizes provided
by prescribing and billing databases usually provide substantial
statistical power for the planned analyses. Of greater concern is
the third reason, namely, confounding as an alternative explan-
ation for the observed association. Finally, other systematic
error(s), e.g. differential follow-up between comparison groups,
can result in an incorrect assessment of the association. Com-
bined with high statistical power, these biases may lead to a ﬁnal
estimate with a low P-value and very narrow conﬁdence inter-
vals: a very precise association, but not a causal one [7]. These
errors may be difﬁcult to overcome unless the necessary data to
control for such biases have been collected and accounted for in
the analysis. Most data sources from routine care are patchy
with regard to variables important to renal outcomes [8].
Therefore, caution is needed when reviewing renal pharmacoe-
pidemiology studies.
STUDY DESIGN
It is appropriate to remind ourselves of the possible designs that
a study may adopt to assess the effects of a drug exposure on a© The Author 201 . Published by Oxford University Press on behalf of ERA-
EDTA. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium,
provided the original work is properly cited.
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disease outcome (Figure 2). Cross-sectional studies cannot con-
ﬁrm a sequence of events in terms of drug exposure and out-
come and are not discussed. Case–control studies are usually
nested in a deﬁned cohort to avoid selection bias. The recently
published studies exploring the relationship between PPI use
and risk of CKD have used cohort designs (Table 1). Because
the chosen outcome was CKD, at baseline there should be no
participant having CKD.
Deﬁnition of the cohort
In the paper by Lazarus et al. [1], the ﬁrst cohort is deﬁned
by participation in the Atherosclerosis Risk in Communities
(ARIC) study, although with some limitations to ensure normal
baseline eGFR and data completeness. This study has all the
strengths of a well-designed prospective cohort, including thor-
ough measurement of baseline covariates such as proteinuria
(often poorly measured in routine data). In contrast, the second
cohort is based within the Geisinger Health System (Pennsylva-
nia, USA), a data source that provides large power but has the
issues of incomplete and biased recording typical of routinely
collected health care data [8]. Participants entered when they
ﬁrst had measurements of both creatinine (equating to an
eGFR >60 mL/min/1.73 m2) and systolic blood pressure avail-
able. In the paper by Xie et al. [2], participants (US veterans)
had to have an eGFR >60 mL/min/1.73 m2 in the 90 days before
receiving the ﬁrst PPI prescription and a subsequent eGFR.
This restriction is important to identify those without CKD.
These deﬁnitions promote inclusion of participants who are
being closely monitored, which may affect the generalizability
of the study, but unless monitoring is different between the
comparison groups, there should be limited bias.
Prevalent versus new-user (incident) cohort
Inclusion of existing users of a drug to deﬁne comparison
groups may create bias since participants who remain on treat-
ment have not yet developed substantial side effects or have a
different indication to remain on the drug versus short-term
users. Sometimes, even protective associations can be found,
as for example in studies of hormone replacement therapy
and vascular outcomes in women [9]. Conversely, people who
remain on long-term treatment may be more sick than those
who only take treatments for short periods, and therefore are
generally more likely to develop conditions like acute kidney in-
jury (AKI) or CKD. Therefore, ‘new-user cohorts’ are preferred
in pharmacoepidemiology, particularly to examine side effects,
such as AKI, that may occur shortly after starting treatment
with a drug [10]. The paper by Lazarus et al. [1] is based on
prevalent PPI use but includes a new-user sensitivity analysis,
while the paper by Xie et al. [2] is based on a new-user cohort.
Choice of comparison group
The gold-standard way of determining drug efﬁcacy and ad-
verse effects is the randomized clinical trial. Fundamentally this
is because, if adequately powered and with a successful alloca-
tion procedure, randomization ensures that there is a balance of
both measured and unmeasured confounders between the
study arms. Similarly, comparison of effects between drugs,
or between treatment and none, is also commonly assessed in
F IGURE 1 : The relationship between PPIs and CKD has caused
much discussion on social media [6] (colour image available online).
F IGURE 2 : Schema of different study designs in pharmacoepidemiology (colour image available online).
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observational studies. It can provide robust results reproducing
clinical trial outcomes if there is a high degree of randomness
between choices of drugs [11]. However, as use of a type of
medication becomes widespread and when drugs are clearly in-
dicated for speciﬁc conditions, the results of these study designs
can be misleading. Such ‘confounding by indication’ may ex-
plain in part many drug-related adverse outcomes seen in ob-
servational studies.
The study question was whether PPI users are more likely to
develop CKD than people not using PPIs. It is probable that
people who do not use PPIs are less ill than PPI users. There-
fore, both of these studies (at least in part) compare outcomes
between users of PPIs and H2-blockers and ﬁnd an increased
incidence of CKD among those exposed to PPIs. But, although
prescribed for similar indications, to what extent are H2-
-blockers a valid comparator for PPI users?We need to consider
the patterns of use of each class of drug at the time that patients
entered the study and compare the measured characteristics of
each group.
In the primary analysis of the ARIC cohort by Lazarus et al.
[1], patients were included between 1996 and 1999. However,
there are very few PPI users (n = 322) in the main analysis and
the date of entry (1996–99) limits the generalizability to current
clinical care. What are the factors that would have led to being
prescribed each class of drug at this time, when PPIs had been
available for a shorter period and were still under patent? New
and expensive drugs are often channelled to sicker patients for
whom more familiar established treatments may have failed.
In the paper by Xie et al. [2], there was a ﬁxed window for
inclusion into the cohort between 2006 and 2008. There were
marked differences in the proportion of users of each class iden-
tiﬁed to have indications for prescribing (e.g. 4.6% of PPI users
had codes indicating upper gastrointestinal (GI) tract bleeding
compared with 1.2% of H2-blocker users). Participants deﬁned
as H2-blocker users could not have received a PPI prior to 2006,
whereas the PPI users could have received an H2-blocker. Since
the study design meant that H2-blocker users could not have
been prescribed a PPI previously, why would a patient be
Table 1. Study design features of pharmacoepidemiology studies published by Lazarus et al. [1], and Xie et al. [2] that investigated the association of PPI use
and CKD as well as AKI
Lazarus et al. Xie et al.
Study design
features
ARIC study Geisinger Health System Department of Veterans Affairs national
databases
Population
studied
ARIC study participants with eGFR≥60
mL/min/1.73 m2 and complete baseline data
(at visit 4 of the original ARIC study)
eGFR≥60 mL/min/1.73 m2 documented
and available blood pressure result
eGFR >60 mL/min/1.73 m2 in the 90 days
before receiving the ﬁrst PPI prescription and
at least one eGFR after the prescription.
(slightly different for H2-blocker users, see
below)
Year of entry into
cohort
1996–99 1997–2014 2006–08
Prevalent or
incident drug
exposure
PPI prevalent users PPI prevalent users, PPI new users sensitivity
analysis
PPI new users
Deﬁnition of
drug exposure
Direct visual inspection of pill bottles for all
medications used during the preceding 2
weeks
PPI prescription within 90 days before
baseline
At least one PPI prescription between
October 2006 and September 2008
Comparison
cohort
Nested within the study population, on H2
blockers or PPI non-users
Nested within the study population, on H2
blockers or PPI non-users
eGFR >60 mL/min/1.73 m2 in the 90 days
before H2-blocker prescription and at least
one eGFR after the prescription. H2-blocker
users could not have received a PPI prior to
2006. Participants could not be deﬁned as
H2-blocker users if they subsequently received
a PPI prescription during follow-up.
Outcome
deﬁnition
Incident CKD and AKI were deﬁned by
ICD-9 coding at discharge, death (ICD-10
code) or by incident ESRD, as determined
through linkage with the USRDS registry
Incident CKD was deﬁned as the ﬁrst
outpatient eGFR <60 mL/min/1.73 m2 that
was sustained at all subsequent assessments
of the eGFR, or ESRD deﬁned through
USRDS linkage.
AKI was deﬁned by ICD-9 coding.
First eGFR <60 mL/min/1.73 m2
(encompassing both CKD and AKI), and
CKD deﬁned as two eGFRs <60 mL/min/
1.73 m2 at least 90 days apart.
AKI deﬁned as 50% serum creatinine increase
or 0.3 mg/dL change within 30 days.
Confounders
adjusted for
Study centre, age, gender, race, education,
health insurance, household income, eGFR/
urinary ACR at baseline, smoking status,
BMI, systolic blood pressure, hypertension,
diabetes, cardiovascular disease,
concomitant medication use including
antihypertensives, anticoagulants and
NSAIDs
Age, gender, race, eGFR at baseline, smoking
status, BMI, systolic blood pressure,
hypertension, diabetes, cardiovascular
disease, concomitant medication use
including antihypertensives, statins, aspirin,
anticoagulants and NSAIDs
Age, gender, race, eGFR at baseline,
hypertension, diabetes, chronic lung disease,
peripheral artery disease, cardiovascular
disease, cerebrovascular disease, dementia,
hepatitis C, HIV, gastro-oesophageal reﬂux
disease, upper GI bleeding, ulcer disease,
Helicobacter pylori infection, Barrett
oesophagus, achalasia, stricture, oesophageal
adenocarcinoma.
In sensitivity analyses: NSAID use, urinary
ACR, serum bicarbonate, ACE-I/ARB use.
BMI, body mass index; ACR, albumin:creatinine ratio; NSAIDs, non-steroidal anti-inﬂammatory drugs; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker.
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prescribed an H2-blocker ﬁrst line, many years after PPIs were
introduced? Cost may have been relevant but is not commented
on. In addition, participants could not be deﬁned as H2-blocker
users if they ever subsequently received a PPI prescription. Both
of these criteria bias substantially towardsH2-blocker users being
healthier than PPI users. Use of ‘future information’ to deﬁne
comparison groups is problematic, as it reduces comparability
to a randomized trial and can also create complex time-related
biases [12]—in this case excluding from theH2-blocker compari-
son group patients who required more aggressive antisecretory
therapy and who are more likely to have multimorbidity.
In both studies it seems likely that PPIs were prescribed for
those with more severe upper GI comorbidities such as ulcer-
ation and bleeding, which were also indicators of poorer health
status. This may be associated with a greater risk of subsequent
CKD. Since prescribing indications are not available for the
ARIC participants, this difference in health status is not clear
from the comparison of baseline characteristics, but the state-
ment that H2-blockers were ‘prescribed for the same indication
as PPIs’ is certainly questionable.
To understand whether differences at baseline between the
two groups will affect the results of the study, the question
now is whether the two groups are otherwise similar in every
important aspect with regard to their risk of the outcome.
This requires a detailed understanding of the risk factors for
the outcome.
Outcome deﬁnition
For the ARIC cohort, incident CKD and AKI were deﬁned by
International Classiﬁcation of Diseases, Ninth Revision (ICD-9)
coding or by incident ESRD, as determined through linkagewith
the United States Renal Data System (USRDS) registry. Deﬁning
incident CKDwith an ICD-9 code requires a patient to be admit-
ted to hospital to get a diagnosis. Patients who are admitted to
hospital need to be able to afford testing and/or admission,
and so there may be socio-economic factors that prevent a timely
diagnosis of CKD. Also, if PPI users were sicker and more often
admitted to hospital than users of H2-blockers, then they may
have been more likely to receive an ICD-9 code of CKD.
For the Geisinger Health System cohort, incident CKD was
deﬁned as the ﬁrst outpatient eGFR <60 mL/min/1.73 m2 that
was sustained at all subsequent assessments of the eGFR, or
ESRD deﬁned throughUSRDS linkage. This outcome is speciﬁc
for the development of sustained CKD.
In the paper by Xie et al. [2], the primary outcomes were the
ﬁrst eGFR <60 mL/min/1.73 m2 (encompassing both CKD and
AKI), and CKD deﬁned as two eGFRs <60 mL/min/1.73 m2 at
least 90 days apart.
Use of a CKD end point based on two measurements re-
quires patients to stay alive for the second measurement to fulﬁl
the chronicity deﬁnition. If sicker patients die beforehand or do
not attend for repeat tests, they would not be coded as having
CKD, which would bias the study towards the null. On the other
hand, physicians may be more likely to monitor renal function
regularly in those they consider to be at higher risk.
Both papers also examined an association between PPI ex-
posure and AKI as an additional outcome. Demonstrating an
association with a second outcome may substantially strengthen
an argument for causality in a pharmacoepidemiological analysis,
particularly where the second outcome may be on the causal
pathwayas is proposed forAKI andCKD.However, in these stud-
ies the outcomes are closely correlated: in the paper by Lazarus
et al. [1], both are deﬁned by ICD-9 coding, while in that by
Xie et al. [2], both CKD and AKI are deﬁned by the change in
creatinine values. For the hospital-derived coding of AKI there
has been a huge change in recognition (similar to that of CKD)
over the past decade [13]. Determining AKI by changes in cre-
atinine appears slightly more robust (than clinical coding), but
the problem of sicker patients being more closely monitored re-
mains.Within each cohort, the same problems apply to both out-
comes, respectively. Therefore, it is unsurprising that an
association between PPI use and AKI is found in both papers.
STATISTICAL ANALYSIS
As observational data are not derived from a randomized con-
trolled study, we cannot be sure that at baseline PPI users are
directly comparable to users of H2-blockers in every respect.
If at baseline there are systematic differences between the two
groups, and these systematic differences affect the outcome ei-
ther through being a risk factor for the outcome (confounding)
or through differential outcome assessment (outcome mis-
classiﬁcation), then there is scope for bias.
Adjusting for confounding
The Lazarus et al. [1] study demonstrated that age, gender,
race, eGFR at baseline, BMI, hypertension (and antihyperten-
sive drug prescription), cardiovascular disease (and prescrip-
tion of aspirin and statins) and anticoagulant use were all
associated with PPI use. Many of these are also risk factors
for CKD. In addition, CKD is associated with socio-economic
status [14], and the Geisinger cohort did not have data on health
insurance. The study by Xie et al. [2] hadmore data on variables
associated with drug indication at baseline, but had to use proxy
variables to capture associations with CKD risk, e.g. instead of
smoking status, adjustments were made for chronic lung and
peripheral vascular disease, and instead of health insurance sta-
tus, other co-variates had to indirectly capture deprivation. The
question is whether these variables are sufﬁcient and well mea-
sured enough to fully adjust for confounding. The authors of
both papers have attempted to understand some of these issues
with additional sensitivity analyses.
Propensity score methods
Both studies include analyses using a propensity score to at-
tempt to adjust for confounding. This analytical technique ex-
amines the effect of the treatment among patients who have the
same predicted probability of receiving the drug, based on their
characteristics when the treatment is chosen. In short, compar-
isons are made between people who are more similar with re-
gard to factors associated with receiving the drug, and therefore
confounding should be reduced. If the propensity score is devel-
oped based on the same covariates as those included in the pri-
mary analysis, there is little evidence that propensity methods
yield substantially different or more accurate estimates than
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those seen after adequate standard multivariable adjustment
[15]. In both types of analysis, elimination of confounding de-
pends on high-quality data and inclusion of all confounders in
the analysis. The main beneﬁt of using propensity scores is to
identify two comparable (matched) groups at baseline. A stand-
ard regression would give an answer in the full study population
but may inadvertently extrapolate beyond the regions of the
data where there is a reasonable comparison to be made. In
the paper by Xie et al. [2] (and probably also that by Lazarus
et al. [1]) there was a large reduction in the number of PPI
users included in the analysis due to individual matching to H2-
-blocker users. The reduced numbers could suggest that H2-
-blocker users are in general not comparable to PPI users in
routine care, but we do not know which kind of PPI user was
left out of the analysis. Reduced comparator numbers also
mean that there is substantially reduced statistical power and
that included PPI users may have been unrepresentative of
PPI users as a whole.
Study era
During the time periods covered by these studies there have
been extensive changes in the patterns of use of acid-
suppressant drugs, with PPIs being increasingly prescribed
[1], and, in addition, the deﬁnitions and recording of AKI
[13] as well as CKD have changed. In 1999, the Modiﬁcation
of Diet in Renal Disease study was published [16] and the
Kidney Disease Outcomes Quality Initiative classiﬁcation was
published in 2002 [17]. As familiarity with the CKD staging sys-
tem has grown, the sensitivity of ICD-9 codes for detection of
CKD have progressively improved [18]. Both papers used Cox
regression tomodel their ﬁnal estimates, and adjustment for the
duration of follow-up within the study is intrinsic to this tech-
nique. If substantial temporal changes affecting data used in an
analysis are suspected, it is common to also adjust for study era
and to conduct sensitivity analyses to examine whether effect
estimates are similar for different periods within the study
[19]. However, it does not appear that either of these studies
also adjusted for calendar time. Both in the Geisinger cohort
and the Xie et al. [2] study, adjustment for available confoun-
ders reduced the effect size. Would further adjustment for other
risk factors (not captured here), including study era, attenuate
the relative risk further?
Time-updated exposure status
In a study of drug effects, people are commonly divided for
analysis into groups based on their drug exposure at baseline
(when they enter the cohort). This is the method used for the
primary analysis of both papers, but it can introduce error
since exposure status may change over the follow-up time.
However, in a secondary analysis in the paper by Lazarus
et al. [1], exposure was also modelled as a time-varying ever-use
variable in which a participant who was a non-user at baseline
switched categories at the ﬁrst instance of PPI use. The nature of
the data meant that the authors could deﬁne when patients
started taking the drugs, but not when they stopped, so all sub-
sequent time was classiﬁed as exposed even if they had stopped
taking PPIs. Although this is an important step in reducingmis-
classiﬁcation, if people taking PPIs are sicker than the
comparator groups, this analysis will not reduce confounding.
Ideally this analysis should also deﬁne periods of time when
people have deﬁnitely stopped taking the drugs, i.e. have not
been prescribed a repeat drug dose, to assess the rate of CKD
during subsequent periods of better health.
Dose response effect
Showing that increasing doses of a drug are associated with
progressively greater risk of the outcome can strengthen argu-
ments for causality in a pharmacoepidemiological study. Both
studies considered here suggest a relationship between the PPI
dose and the incidence of CKD for twice-versus once-daily
dosing in the study by Lazarus et al. [1] and for duration of
exposure in the paper by Xie et al. [2]. However, these ﬁndings
may also be due to confounding: dose frequency may reﬂect the
severity of the indication while the duration of exposure may
suggest an ongoing indication for the drug, both factors that
may be associated with a greater risk of subsequent CKD.
WHAT NEXT?
Both papers produce similar estimates for the increase in risk of
incident CKD among PPI users: in the adjusted models for the
main analysis the hazard ratio was 1.50 [95% conﬁdence inter-
val (CI) 1.14–1.96] in that by Lazarus et al. [1] and 1.28 (95%CI
1.23–1.34) in the paper by Xie et al. [2]. If truly causal, these
effect sizes would be very important for public health due to
the frequency of prescription of PPIs.
A link between PPIs and CKD or AKI is plausible given the
probable link between PPI use and interstitial nephritis [20].
However, PPIs have a long history of being associated with
other illnesses. The paper by Lazarus et al. [1] states that ‘obser-
vational studies have linked PPI use to uncommon but serious
adverse health outcomes, including hip fracture, community
acquired pneumonia,Clostridium difﬁcile infection, acute inter-
stitial nephritis and AKI’. More recently they have also been as-
sociated with dementia [21, 22]. While each is individually
plausible, such a broad spectrum of associated adverse out-
comes all with similar and small effect sizes raises a concern
that the ﬁndings could relate to the same sources of bias.
The challenges of appropriately adjusting for confounding
by indication in the context of who is prescribed PPIs became
apparent during the extensive research into the clinical import-
ance of a pharmacological interaction between clopidogrel and
PPIs on vascular outcomes [23]. The majority of observational
studies compared people taking PPIs and clopidogrel with
those taking clopidogrel alone and found positive associations
of the combination therapy with vascular events. However, im-
portant differences were observed between people prescribed a
PPI and those not prescribed a PPI in terms of risk factors for
vascular events [24]. One study compared the results of two
study designs derived from the same dataset of patients in
UK primary care to investigate the role of residual confounding
[25]. The traditional cohort design showed an increased risk of
vascular events in people taking PPIs and clopidogrel compared
with clopidogrel alone, but tellingly, the cohort study also iden-
tiﬁed an association between PPIs and harmful outcomes that
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would not be predicted by the drug interaction (despite adjust-
ing for relevant recorded confounders), pointing towards re-
sidual confounding as a possible explanation. In the same
study, a self-controlled case series analysis, a method that
compares time periods within individuals to remove between-
person confounding, showed no increase in risk within indivi-
duals when they were taking both drugs. This suggested that the
possible observed interaction between clopidogrel and PPIs was
not of clinical importance and that ﬁndings of harm in the mul-
tiple previous cohort studies were explained by confounding by
poorer health among people taking PPIs that was difﬁcult to ad-
just for in standard analyses.
The importance of assessing bias cannot be overstated, and
only very thorough investigation with a range of study designs
or alternative outcomes will unveil its inﬂuence. Alternative
negative outcomes to understand the degree of residual con-
founding in future studies of the PPI–CKD question may be
useful, for example, incident depression or cataract surgery.
Because CKD is not an acute event, a self-controlled case series
design is not suited to the study of CKD. A self-controlled case
series of the association of PPI use with AKI has not yet been
conducted but may be informative.
CONCLUSION
Bearing in mind the history of PPI-associated adverse event re-
search and the potential sources of bias, we do not believe that
these papers on their own provide strong evidence of a causal
link with CKD. This caution has also been expressed by the
authors, e.g. Lazarus et al. [1] state ‘further research is required
to investigate whether PPI use itself causes kidney damage’,
while Xie et al. [2] state ‘the ﬁndings should not deter from pre-
scription and use of PPI where medically indicated’. Nonethe-
less, there is no doubt that many patients remain on PPIs for
long periods with no clear indication. Studies such as these
serve as salutary reminders to constantly review whether all
drugs remain indicated for each patient, and to de-prescribe if
necessary. Stopping PPIs can cause an exacerbation of severe
dyspeptic symptoms, and inevitably some patients may suffer
more severe complications, for instance, upper GI bleeding
(as one of the high-risk consequences), after cessation.
One may argue that decisions about prescribing are best in-
formed by an overall risk–beneﬁt analysis derived from well-
conducted clinical trials. However, in reality, many such trials
will not be feasible (e.g. for rare harms), nor affordable, nor al-
ways ethical. If done well, observational data have a great deal to
contribute to our understanding of the incidence and causes of
prescribing-related adverse outcomes in routine clinical care.
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